NEXT-GENERATION NK CELL-BASED IMMUNOTHERAPIES FOR HARD-TO-TREAT CANCERS
Associate Professor Fernando S. F. Guimaraes, PhD, GAICD
Group Leader, Translational Innate Immunotherapy
Frazer Institute, Faculty of Medicine,
The University of Queensland, Australia
RESEARCHER PROFILE
Filmed in Brisbane, Australia | February 2025
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
A/Prof Guimaraes completed his PhD at the Institut Pasteur and pursued postdoctoral research at QIMR Berghofer and WEHI before joining UQ in 2019. His pioneering work has significantly advanced understanding of immune evasion mechanisms in cancer, leading to potential breakthroughs in NK cell therapies. His research integrates systems biology, experimental oncology, and bioinformatics to design novel, targeted treatments resistant to tumour-induced immunosuppression. His contributions have earned him numerous awards, including the QLD Tall Poppy, UQ Frazer Institute Rising Star, Translational Research Institute – Connecting with the Clinic Awards.
He has published extensively in top-tier journals, secured and led major research funding (NHMRC, MRFF, US DoD) focused on NK cell therapies. A/Prof Guimaraes also plays a key role in mentoring early-career researchers, serving as the Chair of the Research Committee at Cure Cancer Australia and leading multiple international collaborations.
Source: supplied
https://orcid.org/0000-0002-2037-8946
-
Liver cancer & patient-derived tumour organoids
Dr Benjamin Dwyer is a translational cancer researcher driven by a clear purpose: to ensure discoveries made in the laboratory genuinely improve outcomes for patients.
Based at Curtin University, he established and now leads the organoid platform within the Liver Cancer Collaborative and directs the WA Organoid Innovation Hub, working at the intersection of biology, medicine and biotechnology to accelerate new treatments for liver cancer.
-
Environmental exposure to function of lung epithelial stem cell biology
Dr Clare Weeden has recently commenced as a Laboratory Head at WEHI in 2025, supported by the CSL Centenary Fellowship.
Dr Weeden specialises in lung epithelial cell biology in the context of homeostasis, inflammation, and lung cancer, particularly in people who don’t smoke. Her work endeavours to understand how past environmental exposures shape the responses of lung cells and the molecular mechanisms underlying this cellular recall, with the aim to develop novel early detection strategies for lung disease.
-
Optimising Rural Musculoskeletal Health
Adnan Asger Ali is a Director of Accelerate Physiotherapy and PhD candidate at The University of Sydney, where he is researching implementation strategies for musculoskeletal care pathways in rural Australia as part of the PACE-RURAL project.
A passionate advocate for physiotherapy, Adnan serves as Chair of the Australian Physiotherapy Association’s National Musculoskeletal Committee and sits on the Capital Health Network’s Clinical Council. His commitment to clinical excellence was recognised when he received Physiotherapist of the Year at the 2023 Allied Health Awards.
